User profiles for Ryan Zarychanski
 | Ryan ZarychanskiAssociate Professor, Internal Medicine, Sections of Critical Care and Hematology/Medical … Verified email at umanitoba.ca Cited by 37820 |
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
…, AM Turner, FL van de Veerdonk, R Zarychanski… - Medrxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Critically ill patients with 2009 influenza A (H1N1) infection in Canada
Context Between March and July 2009, the largest number of confirmed cases of 2009
influenza A(H1N1) infection occurred in North America. Objective To describe characteristics, …
influenza A(H1N1) infection occurred in North America. Objective To describe characteristics, …
[HTML][HTML] A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
…, G Drobot, N Marten, R Zarychanski… - New England journal …, 2020 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial
…, F van de Veerdonk, B Venkatesh, R Zarychanski… - Jama, 2020 - jamanetwork.com
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19)
is limited. Objective To determine whether hydrocortisone improves outcome for …
is limited. Objective To determine whether hydrocortisone improves outcome for …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
…, F van de Veerdonk, S Webb, R Zarychanski… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and …
Importance Hydroxyethyl starch is commonly used for volume resuscitation yet has been
associated with serious adverse events, including acute kidney injury and death. Clinical trials …
associated with serious adverse events, including acute kidney injury and death. Clinical trials …
[HTML][HTML] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
…, N Shehata, AF Turgeon, H Wood, R Zarychanski… - Nature medicine, 2021 - nature.com
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …
Although most randomized controlled trials have shown negative results, uncontrolled studies …
Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions worldwide.
Given the rapidly growing evidence base, we implemented a living guideline model to …
Given the rapidly growing evidence base, we implemented a living guideline model to …
Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis
A Kumar, R Zarychanski, B Light, J Parrillo… - Critical care …, 2010 - journals.lww.com
Background: Septic shock represents the major cause of infection-associated mortality in
the intensive care unit. The possibility that combination antibiotic therapy of bacterial septic …
the intensive care unit. The possibility that combination antibiotic therapy of bacterial septic …